Cassava Sciences Files 8-K on Director Changes
Ticker: FLNA · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: SAVA
TL;DR
Cassava Sciences (SAVA) filed an 8-K today - board and exec comp changes expected.
AI Summary
On December 12, 2025, Cassava Sciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on dollar amounts and new appointments are not yet fully disclosed in this initial report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategy and financial management.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- December 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Principal business address
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors as an item of information, but the specific names and details of any new directors or departures are not provided in the summary text.
Are there any details on new executive appointments?
The filing lists 'Appointment of Certain Officers' as an item, but specific names or roles of newly appointed officers are not detailed in the provided text.
What is the nature of the 'Compensatory Arrangements of Certain Officers' mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item, but the specific details, including any dollar amounts or changes to compensation, are not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 12, 2025.
What is Cassava Sciences, Inc.'s primary business address?
Cassava Sciences, Inc.'s primary business address is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-12-17 16:12:28
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA Nasdaq Capital Market
Filing Documents
- sava20251217_8k.htm (8-K) — 29KB
- 0001437749-25-038157.txt ( ) — 156KB
- sava-20251212.xsd (EX-101.SCH) — 3KB
- sava-20251212_def.xml (EX-101.DEF) — 11KB
- sava-20251212_lab.xml (EX-101.LAB) — 15KB
- sava-20251212_pre.xml (EX-101.PRE) — 11KB
- sava20251217_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, the Board of Directors (the "Board") of Cassava Sciences, Inc. (the "Company") approved cash bonus awards for calendar 2025 for the Company's named executive officers in recognition of their contributions to the Company as follows: Name Title Bonus Amount Richard J. Barry President & Chief Executive Officer $ 355,000 Eric J. Schoen Chief Financial Officer $ 215,000 For 2025, the Board established performance measures and goals which were designed to be challenging yet achievable with strong management performance, focused primarily on (1) exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy, (2) building a team with appropriate expertise in TSC-related epilepsy, and (3) budgeting and expense management.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: December 17, 2025 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer